about
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavitiesEvaluation of the specificity of [(18)F]fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [(18)F]FDG and impact of rituximab therapyAppropriateness criteria of FDG PET/CT in oncology.Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI.Quantitative Imaging Analysis of FDG PET/CT Imaging for Detection of Central Neurolymphomatosis in a Case of Recurrent Diffuse B-Cell Lymphoma18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted ImagingUS Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario.FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria.Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease.Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma.Intra- and inter-observer agreement in the visual interpretation of interim 18F-FDG PET/CT in malignant lymphoma: influence of clinical information.Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study.Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials.
P2860
Q28651176-70974BD1-9536-4875-ABC1-2210EE057C54Q33758646-648D0338-FB38-47BF-BC10-9C72F008E3C2Q35554535-DCA9EA20-0E14-4B8B-813C-E54BFAA5DE14Q35568776-A76F7135-5427-4C0F-B41F-DC3B7466BD78Q36057936-B8C33F87-584D-4D56-A61F-ABA52395A951Q36399589-5261D2D9-13CA-45E4-B00E-6C371CB151E6Q36564214-22AD8706-9749-4814-8245-F51CBBCCFF6EQ37138259-42AAE3B1-F304-49DE-ABAA-C75F7B89B7DCQ37428422-EC1738BF-6A57-481A-BC50-51F64867653CQ37605897-3DEEF025-68B2-478D-B1C7-3D4EF360251CQ37639665-67A7366D-C9F0-41C2-B2B4-DE4FD1FA34C1Q38663136-C45157BF-C482-4207-B041-B1A31B645194Q41481956-A8CBBCAE-FAC7-4F5C-A9FE-330C16992BAEQ48218642-5A8D574D-735A-4A4E-9644-77AA2AC825C7Q50047838-81E815E8-5B22-4C08-AB34-A0ED71D41BF3Q50918860-A3256F08-44EB-4BF7-BC49-D12686673BC4Q52685638-2A7FB95F-BCAF-4A57-B05A-D4E84DADE7FCQ53058794-35F33E9A-966D-4542-B18E-A5861423497BQ54152231-82B107C1-ADA4-4076-83FD-153AECE73680
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Current role of FDG PET/CT in lymphoma.
@en
type
label
Current role of FDG PET/CT in lymphoma.
@en
prefLabel
Current role of FDG PET/CT in lymphoma.
@en
P2860
P1476
Current role of FDG PET/CT in lymphoma.
@en
P2093
Bruce D Cheson
Lale Kostakoglu
P2860
P2888
P304
P356
10.1007/S00259-013-2686-2
P577
2014-02-12T00:00:00Z